Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito
View: Text | PDF
Research Article Hepatology Virology

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response

  • Text
  • PDF
Abstract

Hepatitis delta virus (HDV), a satellite virus of HBV, is regarded as the most severe type of hepatitis virus because of the substantial morbidity and mortality. The IFN system is the first line of defense against viral infections and an essential element of antiviral immunity; however, the role of the hepatic IFN system in controlling HBV-HDV infection remains poorly understood. Herein, we showed that HDV infection of human hepatocytes induced a potent and persistent activation of the IFN system whereas HBV was inert in triggering hepatic antiviral response. Moreover, we demonstrated that HDV-induced constitutive activation of the hepatic IFN system resulted in a potent suppression of HBV while modestly inhibiting HDV. Thus, these pathogens are equipped with distinctive immunogenicity and varying sensitivity to the antiviral effectors of IFN, leading to the establishment of a paradoxical mode of viral interference wherein HDV, the superinfectant, outcompetes HBV, the primary pathogen. Furthermore, our study revealed that HDV-induced constitutive IFN system activation led to a state of IFN refractoriness, rendering therapeutic IFNs ineffective. The present study provides potentially novel insights into the role of the hepatic IFN system in regulating HBV-HDV infection dynamics and its therapeutic implications through elucidating the molecular basis underlying the inefficacy of IFN-based antiviral strategies against HBV-HDV infection.

Authors

Takeshi Chida, Yuji Ishida, Sho Morioka, Go Sugahara, Christine Han, Bill Lam, Chihiro Yamasaki, Remi Sugahara, Meng Li, Yasuhito Tanaka, T. Jake Liang, Chise Tateno, Takeshi Saito

×

Figure 2

HDV coinfection limits the HBV life cycle through the activation of the IFN system in hepatocytes.

Options: View larger image (or click on image) Download as PowerPoint
HDV coinfection limits the HBV life cycle through the activation of the ...
(A) HLCM-HH were coinfected with HBV (MOI 50) and HDV (5,000 GEq/cell) for indicated durations. The culture supernatants were subjected to the quantification of HBV DNA and HDV RNA (top, left) via RT-qPCR as well as HBeAg (top, right) and HBsAg (bottom, right) with ELISA. Total cellular RNA at each time point was also subjected to the quantification of HBV pgRNA and HDV RNA via RT-qPCR (bottom, left). Results are shown as mean ± SD of triplicate samples. *P < 0.05, ***P < 0.001 were determined by 1-way ANOVA with post hoc Tukey’s test. HBeAg, HBV e antigen; pgRNA, pregenomic RNA; PEI, Paul-Ehrlich international. (B) IFA image of HLCM-HH coinfected with HBV and HDV. Green, HBV Core; red, HDAg; blue, DAPI. Scale bar: 50 μm. The percentage shown in the image indicates the median HBV Core, HDAg, or HBV Core-HDAg dual-positive foci/total number of cells. (C and D) RNA-Seq analysis of HLCM-HH infected with mock virus, HBV, or HBV-HDV coinfection for 15 days. The hierarchical clustering demonstrates the differentially regulated genes (DEGs) (cutoffs used were a P value of 0.01 and a fold-change [FC] of 2) (C) and the heatmap analysis of ISGs included in the DEGs (D). (E and F) HLCM-HH were either mono-infected with HBV or coinfected with HBV-HDV in the presence of TOF (10 μM) for 10 days followed by IFA of indicated molecules (E) or RT-qPCR analysis of HBV DNA and HDV RNA present in the culture supernatant (F). Scale bar: 50 μm. The percentage shown in the image indicates the median HBV Core–positive (top) or HDAg-positive (middle) foci/total number of cells. Results are shown as mean ± SD of triplicate samples. **P < 0.01, ***P < 0.001 were determined by 1-way ANOVA with post hoc Tukey’s test. Displayed data represent one of the biological triplicate experiments (A, B, E, and F).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts